However, the clinical benefits of first- and second-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs) are limited in NSCLC, pancreatic cancer, and glioblastoma due to drug resistance [14,15,16,17,18,19,20,21]. Here, EGFR is linked to non-small cell lung carcinoma.